Brief: Ascidian Therapeutics Announces Global Research Collaboration Licensing Agreement With Eli Lilly
03/06/2026 12:00
BRIEF-Ascidian Therapeutics Announces Global Research Collaboration Licensing Agreement With Eli Lilly June 3 (Reuters) - Ascidian Therapeutics:
ASCIDIAN THERAPEUTICS: ANNOUNCES GLOBAL RESEARCH COLLABORATION LICENSING AGREEMENT WITH ELI LILLY
ASCIDIAN THERAPEUTICS: LILLY TO RECEIVE EXCLUSIVE TARGET-SPECIFIC RIGHTS TO CO'S RNA EXON EDITING TECHNOLOGY FOR UNDISCLOSED KIDNEY DISEASE TARGETS
ASCIDIAN THERAPEUTICS: ELIGIBLE TO RECEIVE UP TO $1.9 BLN
ASCIDIAN THERAPEUTICS: UNDER DEAL, LILLY RESPONSIBLE FOR ADDITIONAL CLINICAL DEVELOPMENT, MANUFACTURING, AND COMMERCIALIZATION
ASCIDIAN THERAPEUTICS: RETAINS RIGHT TO PURSUE OTHER TARGETS IN KIDNEY DISEASE PROGRAMS INDEPENDENTLY OR WITH ADDITIONAL PARTNERS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eli Lilly and Co
See all newsAntares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Absci rises on positive hair-loss drug data
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
HK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)